Drug Profile
Lpathomab
Alternative Names: Anti-LPA MAbs - Lpath; Lpathomab; mAb against lysophosphatidic acid (LPA) - LpathLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Lpath
- Developer Lpath; University of California at Los Angeles; University of Melbourne
- Class Monoclonal antibodies
- Mechanism of Action Lysophosphatidic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Brain injuries; Cancer; Diabetic neuropathies; Fibrosis; Neuropathic pain; Spinal cord injuries
Most Recent Events
- 22 Feb 2023 Discontinued - Phase-I for Neuropathic pain (In volunteers) in USA (Parenteral)
- 22 Feb 2023 Discontinued - Preclinical for Brain injuries in Australia (Parenteral)
- 22 Feb 2023 Discontinued - Preclinical for Brain injuries in USA (Parenteral)